NCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2024-06-05Est. Completion: 2028-10-30

Enrollment target: 1,200 participants

Locations

Digestive Health Specialists ( Site 5064), Dothan, Alabama, United States
Arizona Arthritis & Rheumatology Research, PC ( Site 5094), Phoenix, Arizona, United States
GI Alliance - Sun City ( Site 5118), Sun City, Arizona, United States
University of Arizona Clinical and Translational Sciences Research Center ( Site 5111), Tucson, Arizona, United States
University of Arkansas for Medical Sciences ( Site 5147), Little Rock, Arkansas, United States
Clinnova Research ( Site 5110), Anaheim, California, United States
Southern California Research Center ( Site 5044), Coronado, California, United States
Om Research LLC ( Site 5038), Lancaster, California, United States
Cedars Sinai Medical Center ( Site 5080), Los Angeles, California, United States
UCLA Clinical & Translational Research Center (CTRC) ( Site 5116), Los Angeles, California, United States
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 5128), Orange, California, United States
Om Research LLC ( Site 5045), Oxnard, California, United States
Clinical Applications Laboratories ( Site 5123), San Diego, California, United States

Inflammatory Bowel DiseaseCrohn's DiseaseUlcerative Colitis

Background: Inflammatory bowel disease (IBD) is a term used to describe disorders that cause long-term inflammation in …

Bethesda, United StatesEst. completion Jun 1, 2036

Inflammatory Bowel Disease

Crohn's Disease (CD) and Ulcerative Colitis (UC), collectively known as inflammatory bowel disease (IBD), are two of the…

Chicago, United StatesEst. completion Sep 1, 2026

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.